Open an account

Xilio Therapeutics

XLO · NASDAQ

$8.54+$0.21 (+2.52%)TodayMarket closed ·
Prev close $8.33

About XLO

Xilio Therapeutics, Inc. operates as a biotechnology company. The company is headquartered in Waltham, Massachusetts and currently employs 76 full-time employees. The company went IPO on 2021-10-22. The firm is engaged in discovering and developing masked immuno-oncology, or I-O, therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. Its pipeline products include Vilastobart, Efarindodekin alfa, XTX501, and masked T cell engagers. Vilastobart is an investigational masked, Fc-enhanced anti-CTLA-4 designed to block CTLA-4 and deplete regulatory T cells when activated (unmasked) in the tumor microenvironment (TME). XTX501 is a novel bispecific PD-1 / masked IL-2 designed to selectively stimulate PD-1 positive, antigen-experienced T cells and enhance their function. Its masked T cell engager programs consist of PSMA and STEAP1 with co-stimulation and CLDN18.2. The masked T cell engagers include molecules with one or more tumor-associated antigen (TAA) binding domains and a CD3 targeting domain.

Employees
76
Headquarters
Waltham, Massachusetts
Listed
Oct 22, 2021
Sector
Health Care
Industry
Biotechnology
Website
xiliotx.com

XLO key statistics

Market cap
54.32M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
9.72K
Volume
13.51K
Open price
$8.25
High today
$8.84
Low today
$8.25
52 Week high
$12.58
52 Week low
$6.47

Xilio Therapeutics (XLO) at a glance

Xilio Therapeutics (XLO) last traded at $8.54, with a market cap of 54.32M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $8.25 and $8.84. The current price is 3.5% above the day's low and 3.4% below its high.

Volume so far is 13.51K shares, above the average of 9.72K shares a day.

Over the past year Xilio Therapeutics has ranged from $6.47 to $12.58, and now sits 34% of the way up that range.

Xilio Therapeutics met or beat analyst EPS estimates in 6 of the last 8 quarters. In Q2 FY26 it reported -$0.33 per share against an estimate of -$0.5959.

XLO earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 6 of the last 8 quarters, by 51.0% on average.

  1. Q3 FY24: reported -$3.08 per share against an estimate of -$3.49
  2. Q4 FY24: reported -$2.80 per share against an estimate of -$3.06
  3. Q1 FY25: reported -$2.52 per share against an estimate of $1.34
  4. Q2 FY25: reported -$2.24 per share against an estimate of -$1.13
  5. Q3 FY25: reported -$0.084 per share against an estimate of -$0.4242
  6. Q4 FY25: reported $0.81 per share against an estimate of -$1.70
  7. Q1 FY26: reported -$0.58 per share against an estimate of -$0.6666
  8. Q2 FY26: reported -$0.33 per share against an estimate of -$0.5959

XLO news

  • Press releaseGlobe Newswire

    Xilio Therapeutics Reports Second Quarter 2026 Financial Results and Provides Pipeline and Business Updates

  • Press releaseGlobe Newswire

    Xilio Therapeutics Reports First Quarter 2026 Financial Results and Provides Pipeline and Business Updates

  • 12 Health Care Stocks Moving In Thursday's After-Market Session

  • Press releaseGlobe Newswire

    Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2025 Financial Results

  • 12 Health Care Stocks Moving In Monday's After-Market Session

  • Press releaseGlobe Newswire

    Xilio Therapeutics Announces Pipeline and Business Updates and Second Quarter 2025 Financial Results

  • Avi Kapoor

    Nasdaq Edges Higher; ISM Manufacturing PMI Falls In May

  • Avi Kapoor

    Dow Dips Over 300 Points; Campbell's Posts Upbeat Earnings

Similar companies

Companies in the same industry as Xilio Therapeutics

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.